Investors

Investors’ data

Latest news

July 10, 2008

Thallion Announces 2008 Second Quarter Results

July 7, 2008

Notice of Thallion Pharmaceuticals Fiscal 2008 Second Quarter Conference Call

June 26, 2008

Thallion receives health canada approval to initiate Phase II study for TLN-232 in metastatic melanoma patients- Company initiates Phase II study with its second oncology product -

Documentation

• Second Quarter 2007 Results Conference Call